Continued Access to HIV Treatment for People Finishing Earlier ViiV Healthcare Studies
Lets people with HIV keep taking study drugs after earlier ViiV studies end.
Plain-language title generated from the registry record
Registry title: A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
Key facts
- Where
- Durban, Gauteng, Johannesburg, and Jouberton, South AfricaSee the 4 sites
- Phase
- Phase 3
Where in South Africa
- DurbanDurban, South AfricaTaking people
- GautengGauteng, South AfricaTaking people
- JohannesburgJohannesburg, South AfricaTaking people
- JoubertonJouberton, South AfricaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ViiV Healthcare
- Trial code
- NCT07393659
- Record updated
- 14 August 2026
- Original description
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.Read full original descriptionShow less
A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
Inclusion: Investigator confirmation of the participant's continued clinical benefit from the parent study intervention and the participant's completion of the protocol-defined treatment period in the parent study. The Investigator should ensure that the participant is still eligible for the parent study (i.e., have not met parent study discontinuation/ withdrawal criteria); Participants or legally authorized representative (LAR) who are willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in the applicable appendix and determined by the Investigator; Participant or LAR is able and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and this protocol. Where applicable, participants must provide written assent.
Exclusion: Any reason that, in the opinion of the Investigator or Sponsor, precludes the participant's inclusion in the study.